troglitazone has been researched along with Cicatrix, Hypertrophic in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Cicatrix, Hypertrophic: An elevated scar, resembling a KELOID, but which does not spread into surrounding tissues. It is formed by enlargement and overgrowth of cicatricial tissue and regresses spontaneously.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Zhu, HY | 1 |
| Li, C | 1 |
| Zheng, Z | 1 |
| Zhou, Q | 1 |
| Guan, H | 1 |
| Su, LL | 1 |
| Han, JT | 1 |
| Zhu, XX | 1 |
| Wang, SY | 1 |
| Li, J | 1 |
| Hu, DH | 1 |
1 other study available for troglitazone and Cicatrix, Hypertrophic
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist inhibits collagen synthesis in human hypertrophic scar fibroblasts by targeting Smad3 via miR-145.
Topics: Anilides; Cells, Cultured; Chromans; Cicatrix, Hypertrophic; Collagen; Collagen Type I; Fibroblasts; | 2015 |